tert-butyl 4-(3-cyanophenoxy)piperidine-1-carboxylate | 950649-06-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-(3-cyanophenoxy)piperidine-1-carboxylate
• 英文别名: tert-butyl 4-(3-cyanophenyloxy)-1-piperidinecarboxylate；tert-butyl 4-(3-cyanophenoxy)-piperidine-1-carboxylate
• CAS: 950649-06-6
• 化学式: C₁₇H₂₂N₂O₃
• mdl: MFCD24393304
• 分子量: 302.373
• InChiKey: SDBVWYQWKOCTJN-UHFFFAOYSA-N

物化性质

• 沸点：
  425.7±40.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.529
• 拓扑面积：
  62.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(3-cyanophenoxy)piperidine-1-carboxylate 在 二异丁基氢化铝 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 tert-butyl 4-(3-formylphenoxy)piperidine-1-carboxylate
  参考文献：
  名称：

  6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

  摘要：

  本发明涉及6,7-二氢-5H-吡咯[3,4-b]吡啶-5-酮化合物，这些化合物是M4毒蕈碱乙酰胆碱受体的变构调节剂。本发明还涉及在本申请中描述的化合物在潜在治疗或预防神经和精神障碍和疾病中的应用，其中涉及M4毒蕈碱乙酰胆碱受体。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及M4毒蕈碱乙酰胆碱受体的疾病的应用。

  公开号：

  US20170183342A1
• 作为产物：
  描述：

  3-氟苯腈 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 17.83h， 以81%的产率得到tert-butyl 4-(3-cyanophenoxy)piperidine-1-carboxylate
  参考文献：
  名称：

  Therapeutic Agents

  摘要：

  本发明提供了公式I的化合物，制备这些化合物的方法，它们在治疗肥胖、精神障碍、认知障碍、记忆障碍、精神分裂症、癫痫以及相关疾病、2型糖尿病、代谢综合征和神经系统疾病如痴呆症、多发性硬化症、帕金森病、亨廷顿舞蹈症、阿尔茨海默病和与疼痛相关的疾病中的用途，以及含有它们的药物组合物。

  公开号：

  US20080051405A1

文献信息

• ISOCARBOSTYRIL ALKALOID DERIVATIVES HAVING ANTI-PROLIFERATIVE AND ANTI-MIGRATORY ACTIVITIES
  申请人：Ingrassia Laurent

  公开号：US20100076005A1

  公开（公告）日：2010-03-25

  Isocarbostyril alkaloid derivatives having an anti-proliferative and anti-migratory activities are disclosed. In particular, compounds of formula (I) or (II), as well as stereoisomers, tautomers, racemates, prodrugs, metabolites thereof, pharmaceutically acceptable salt and/or solvate are encompassed which are useful in the treatment and prophylaxis of cancer. Methods of preparation are also disclosed.

  揭示了具有抗增殖和抗迁移活性的异喹啉生物碱衍生物。具体来说，公开了符合以下化学式(I)或(II)的化合物，以及其立体异构体、互变异构体、消旋体、前药、代谢物、药学上可接受的盐和/或溶剂，这些化合物在癌症的治疗和预防中很有用。还公开了制备方法。
• Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same
  申请人：De Lombaert Stephane

  公开号：US20090111791A1

  公开（公告）日：2009-04-30

  Disclosed are compounds active against soluble epoxide hydrolase (sEH), compositions thereof and methods of using and making same.

  本发明涉及对可溶性环氧酶水解酶（sEH）具有活性的化合物、其组合物以及使用和制备它们的方法。
• Thienopyrimidine compounds and uses thereof
  申请人：AstraZeneca AB

  公开号：US07723331B2

  公开（公告）日：2010-05-25

  The present invention provides compounds of the class of thienopyrimidines, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, type II diabetes, Metabolic syndrome and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, and pain related disorders, and to pharmaceutical compositions containing them.

  本发明提供了一类噻唑嘧啶类化合物，制备这种化合物的方法，以及它们在治疗肥胖症、精神障碍、认知障碍、记忆障碍、精神分裂症、癫痫和相关疾病、2型糖尿病、代谢综合征和神经系统疾病（如痴呆、多发性硬化症、帕金森病、亨廷顿舞蹈病、阿尔茨海默病和与疼痛有关的疾病）的应用，以及含有它们的制药组合物。
• 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
  申请人：Bao Jianming

  公开号：US10329289B2

  公开（公告）日：2019-06-25

  The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

  本发明涉及 6,7-二氢-5H-吡咯并[3,4-b]吡啶-5-酮化合物，这些化合物是 M4 肌 肉碱乙酰胆碱受体的异构调节剂。本发明还涉及本文所述化合物在潜在治疗或预防涉及 M4 肌卡因乙酰胆碱受体的神经和精神障碍及疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及 M4 蕈样乙酰胆碱受体的此类疾病中的用途。
• 6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10351564B2

  公开（公告）日：2019-07-16

  The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

  本发明涉及 6,7-二氢-5H-吡咯并[3,4-b]吡啶-5-酮化合物，这些化合物是 M4 肌 肉碱乙酰胆碱受体的异构调节剂。本发明还涉及本文所述化合物在潜在治疗或预防涉及 M4 肌卡因乙酰胆碱受体的神经和精神障碍及疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及 M4 蕈样乙酰胆碱受体的此类疾病中的用途。